PDF(Pubmed)
Abstract：
UNASSIGNED: Chronic lymphocytic leukemia (CLL) can transform into fast growing lymphoma for diffuse large B-cell lymphoma (DLBCL) called Richter\'s syndrome (RS), which is commonly related to an existence of large B-cells with equal or larger size than macrophage nuclei or more than twice those of normal lymphocyte. We conducted a systematic review of the existing literature to assess the clinical efficacy of auto-HCT for patients with RS.
UNASSIGNED: We searched 4 main databases; EMBASE, Google Scholar, Scopus, PubMed and Web of Science and was done on December 26, 2021. All analyses in this study were performed by Stata software and this review was reported in accordance with PRISMA 2020.
UNASSIGNED: Data was extracted from 4 articles; the total number of patients was reported to be 110. Based on the meta-analysis findings, pooled overall survival rate was 56.36% (95%CI= (46.98-65.31). In figure 2, the forest plot of combined results is shown.
UNASSIGNED: Despite the use of common treatment regimens such as chemo immunotherapy and the availability of novel therapies including B-cell receptor inhibitors and rituximab-cyclophosphamide-hydroxydaunorubicin-Oncovin-prednisone (CHOP-R) regimen, the status of disease progression and recovery in RS cases is still not strong enough.
UNASSIGNED: We searched 4 main databases; EMBASE, Google Scholar, Scopus, PubMed and Web of Science and was done on December 26, 2021. All analyses in this study were performed by Stata software and this review was reported in accordance with PRISMA 2020.
UNASSIGNED: Data was extracted from 4 articles; the total number of patients was reported to be 110. Based on the meta-analysis findings, pooled overall survival rate was 56.36% (95%CI= (46.98-65.31). In figure 2, the forest plot of combined results is shown.
UNASSIGNED: Despite the use of common treatment regimens such as chemo immunotherapy and the availability of novel therapies including B-cell receptor inhibitors and rituximab-cyclophosphamide-hydroxydaunorubicin-Oncovin-prednisone (CHOP-R) regimen, the status of disease progression and recovery in RS cases is still not strong enough.
摘要：
未经证实：慢性淋巴细胞白血病（CLL）可以转化为快速生长的淋巴瘤，用于弥漫性大B细胞淋巴瘤（DLBCL），称为Richter综合征（RS）。这通常与大B细胞的存在有关，其大小等于或大于巨噬细胞核或超过正常淋巴细胞的两倍。我们对现有文献进行了系统回顾，以评估auto-HCT对RS患者的临床疗效。
未经评估：我们搜索了4个主要数据库；EMBASE，谷歌学者，Scopus,PubMed和WebofScience于2021年12月26日完成。本研究中的所有分析均由Stata软件进行，本综述根据PRISMA2020进行报告。
UNASSIGNED：数据来自4篇文章；据报道，患者总数为110。根据荟萃分析的结果，合并总生存率为56.36%(95CI=(46.98-65.31).在图2中,示出了组合结果的森林图。
UNASSIGNED：尽管使用了常用的治疗方案，如化学免疫疗法和新疗法，包括B细胞受体抑制剂和利妥昔单抗-环磷酰胺-羟基柔红霉素-强的松（CHOP-R）方案，RS病例的疾病进展和恢复状况仍然不够强.
未经评估：我们搜索了4个主要数据库；EMBASE，谷歌学者，Scopus,PubMed和WebofScience于2021年12月26日完成。本研究中的所有分析均由Stata软件进行，本综述根据PRISMA2020进行报告。
UNASSIGNED：数据来自4篇文章；据报道，患者总数为110。根据荟萃分析的结果，合并总生存率为56.36%(95CI=(46.98-65.31).在图2中,示出了组合结果的森林图。
UNASSIGNED：尽管使用了常用的治疗方案，如化学免疫疗法和新疗法，包括B细胞受体抑制剂和利妥昔单抗-环磷酰胺-羟基柔红霉素-强的松（CHOP-R）方案，RS病例的疾病进展和恢复状况仍然不够强.
